Tripping Balls in Color for the First Time – Is Psilocybin Helping to Cure Color Blindness One Dose at a Time?

A case report authored by researchers from the Department of Psychiatry and Psychology at the Cleveland Clinic’s Center for Behavioral Health, Neurological Institute in Ohio, looks into the potential benefits of psilocybin for color blindness.

420 420 deals cloud cover giveaway High Profile sponsored article Strains & Products

Celebrate 420 with limited-edition merch at High Profile

Commemorate weed’s biggest day with Cloud Cover’s finest. 420 is here, and High Profile and Cloud Cover have a present, just for you. Now through 4/21, if you spend at least $25 on Cloud Cover’s line of premium flower, pre-rolls, vape…

acquisition All U.S. Ancillary Briefs California cannabis human resources CannabizTeam CannabizTemp Colorado executive search executives gig gig work hiring labor M&A temporary workers Vangst Vangst Gigs

Cannabis staffing company Vangst acquires ‘largest competitor’

Vangst, a major cannabis industry staffing platform, acquired CannabizTemp in what is believed to be the first such move in the marijuana human resources sector.
Cannabis staffing company Vangst acquires ‘largest competitor’ is a post from:…

adolescents cannabis Culture Featured Harvard University John Hopkins marijuana marijuana use Massachusetts Cannabis Control Commission news study teens weed Youth Risk Behavior Survey Data Summary & Trends Report

Legal Cannabis And Adolescent Use

Legal Cannabis And Adolescent Use
The DEA is considering rescheduling. Opponents are upset, but here are the facts about legal cannabis and adolescent use.
The post Legal Cannabis And Adolescent Use appeared first on The Fresh Toast.

All U.S. Briefs cbd FDA Commissioner Robert Califf hemp CBD Hemp Industry News Legal marijuana rescheduling Medical & Recreational recreational retail U.S. Drug Enforcement Administration U.S. Food and Drug Administration U.S. Rep. James Comer

‘No reason’ for DEA to delay marijuana rescheduling, FDA chief says

There’s “no reason” for the U.S. Drug Enforcement Administration to delay its long-awaited decision on moving marijuana from Schedule 1 to Schedule 3 of the Controlled Substances Act, the head of the Food and Drug Administration told a House committee….